<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660942</url>
  </required_header>
  <id_info>
    <org_study_id>202001521A3</org_study_id>
    <nct_id>NCT04660942</nct_id>
  </id_info>
  <brief_title>Child Development and Genetic Biomarkers</brief_title>
  <official_title>Child Development and Genetic Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of the relation between genetic biomarkers and child development in Taiwan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The interaction between gene and environment (GÃ—E) can be a very complicated process that&#xD;
      influences child development. As a pilot study of child development biomarkers, this study&#xD;
      investigates genes related to child development.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Scores of cognitive function 1</measure>
    <time_frame>baseline</time_frame>
    <description>Bayley Scales of Infant and Toddler Development (Scores from 0 to 140, higher scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores of cognitive function (2 y/o to 6 y/o)</measure>
    <time_frame>baseline</time_frame>
    <description>Wechsler Preschool and Primary Scale of Intelligence (Scores from 0 to 200, higher scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores of cognitive function (6 y/o to 16 y/o)</measure>
    <time_frame>baseline</time_frame>
    <description>Wechsler Intelligence Scale for Children (Scores from 0 to 200, higher scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores of cognitive function 3</measure>
    <time_frame>baseline</time_frame>
    <description>Test of Nonverbal Intelligence-Fourth Edition (Scores from 0 to 60, higher scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores of cognitive psychological function</measure>
    <time_frame>baseline</time_frame>
    <description>Cantab MOT, PAL, SWM, SOC tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores of language function</measure>
    <time_frame>baseline</time_frame>
    <description>Peabody Picture Vocabulary Test-Revised (Scores from 0 to 124, higher scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores of language function 2</measure>
    <time_frame>baseline</time_frame>
    <description>Preschool Language Impaired Scale(PLS)/Language Impaired Scale(LS) (PLS: Scores from 0 to 65, higher scores mean a better outcome. LS: Scores from 0 to 73, higher scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores of general development</measure>
    <time_frame>baseline</time_frame>
    <description>Comprehensive Developmental Inventory for Infants and Toddlers (Higher scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores of social behavior 1</measure>
    <time_frame>baseline</time_frame>
    <description>Clancy Behavior Scale (Scores from 0 to 42, lower scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores of social behavior 2</measure>
    <time_frame>baseline</time_frame>
    <description>Swanson, Nolan, and Pelham, Version IV (Lower scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores of motor ability 1</measure>
    <time_frame>baseline</time_frame>
    <description>The Berry-Buktenica Developmental Test of Visual-Motor Integration (Scores from 0 to 81, Higher scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores of motor ability 2</measure>
    <time_frame>baseline</time_frame>
    <description>Measure of Grip and Grasp (Higher scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene test (Mircoarray)</measure>
    <time_frame>baseline</time_frame>
    <description>Microarray (Use Axiom Genome-Wide TWB 2.0 Array Plate (TWB 2.0) to analyze SNPs of disease-related biomarkers.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene test (WES1)</measure>
    <time_frame>baseline</time_frame>
    <description>Whole-Exome Sequencing (Use Burrows-Wheeler Aligner (BWA) 85 to screen out the variant discovery and genotyping.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene test (WES2)</measure>
    <time_frame>baseline</time_frame>
    <description>Whole-Exome Sequencing (Use Samtools86 to screen out the variant discovery and genotyping.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene test (WES3)</measure>
    <time_frame>baseline</time_frame>
    <description>Whole-Exome Sequencing (Use Picard to screen out the variant discovery and genotyping.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene test (WES4)</measure>
    <time_frame>baseline</time_frame>
    <description>Whole-Exome Sequencing (Use Genome Analysis Toolkit (GATK) to screen out the variant discovery and genotyping.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scores of participation(2-5 y/o)</measure>
    <time_frame>baseline</time_frame>
    <description>Assessment of Preschool Children's Participation (Scores from 0 to 45, higher scores mean a better outcome.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores of participation(&gt;6 y/o)</measure>
    <time_frame>baseline</time_frame>
    <description>Children Assessment of Participation and Enjoyment and Preferences for Activity of Children (Higher scores mean a better outcome.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores of activities</measure>
    <time_frame>baseline</time_frame>
    <description>Functional Independence Measure for Children (Scores from 18 to 126, higher scores mean a better outcome.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores of quality of life</measure>
    <time_frame>baseline</time_frame>
    <description>Pediatric Quality of Life Inventory TM (Scores from 0 to 102, higher scores mean a better outcome.)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">446</enrollment>
  <condition>Child Development</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy child</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <description>Patients with developmental delay</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples with DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy children, children with developmental delay and adults whose children had gene&#xD;
        abnormality were recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria of Healthy Child:&#xD;
&#xD;
          -  Age 2-18 y/o&#xD;
&#xD;
          -  Agree to sign informed consent&#xD;
&#xD;
        Exclusion Criteria of Healthy Child:&#xD;
&#xD;
          -  Central nervous system disease&#xD;
&#xD;
          -  Neuromuscular Disorders&#xD;
&#xD;
          -  Congenital Abnormality&#xD;
&#xD;
          -  Genetic Disease&#xD;
&#xD;
          -  Dysesthesia&#xD;
&#xD;
          -  Hearing Impairment&#xD;
&#xD;
        Inclusion Criteria of Child with developmental delay:&#xD;
&#xD;
          -  Patients with Language Disorder&#xD;
&#xD;
          -  Age 2-18 y/o&#xD;
&#xD;
          -  Agree to sign informed consent&#xD;
&#xD;
        Exclusion Criteria of Child with developmental delay:&#xD;
&#xD;
          -  Hearing Impairment&#xD;
&#xD;
        Inclusion Criteria of Adult:&#xD;
&#xD;
          -  His or her child participated in this study, and gene abnormality was found.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia-Ling Chen, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chia-Ling Chen, Phd</last_name>
    <phone>+886-3-3281200</phone>
    <phone_ext>8148</phone_ext>
    <email>clingchen@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia-Ling Chen, MD, PhD</last_name>
      <phone>+886-3-3281200</phone>
      <phone_ext>8148</phone_ext>
      <email>clingchen@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

